Abstract
Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P >.05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 547-550 |
| Number of pages | 4 |
| Journal | Clinical Infectious Diseases |
| Volume | 52 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 15 Feb 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an efavirenz-based regimen'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver